Coriell Institute for Medical Research

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Tuesday, August 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Tuesday, August 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

CI Financial to Acquire Ultra-High-Net-Worth Wealth Manager Coriel Capital

Retrieved on: 
Thursday, August 10, 2023
Professional Services, Other Professional Services, Finance, Asset Management, Consulting, Personal Finance, LLP, CIX, Davies Ward Phillips & Vineberg, CI, Woman, Consultant, Blake, Cassels & Graydon, Partner, Investment, TSX, Growth, Financial services, Financial adviser, Coriell Institute for Medical Research

(“CI”) (TSX: CIX) and Coriel Capital Inc. (“Coriel”) today announced an agreement under which CI will acquire Coriel, a Montreal-based wealth management firm.

Key Points: 
  • (“CI”) (TSX: CIX) and Coriel Capital Inc. (“Coriel”) today announced an agreement under which CI will acquire Coriel, a Montreal-based wealth management firm.
  • Coriel , a firm founded and led by women, operates as a “Chief Investment Officer” for ultra-high-net-worth families, helping them navigate complex financial decisions and ensuring their investments effectively support their goals and are fully integrated into their overall financial plans.
  • “Coriel’s experience, strong performance and service offering have generated excellent growth and we’re pleased to welcome this accomplished team to CI,” said Kurt MacAlpine, CI Chief Executive Officer.
  • Blair Franklin Capital Partners Inc. served as financial advisor to Coriel and Davies Ward Phillips & Vineberg LLP was legal advisor.

Akebia Therapeutics Announces New Chief Financial Officer

Retrieved on: 
Tuesday, June 13, 2023
Benchmark, LLP, Senior, Coriell Institute for Medical Research, New Drug Application, NDA, AKBA, Accounting, PwC, Business administration, Patient, Merrimack College, Harvard Business School, Therapy, Financial management, Market for corporate control, Kidney disease, Ernst & Young, Management, Akebia

CAMBRIDGE, Mass., June 13, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Ellen Snow is joining Akebia as its new Senior Vice President, Chief Financial Officer and Treasurer, beginning on July 17, 2023.

Key Points: 
  • CAMBRIDGE, Mass., June 13, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Ellen Snow is joining Akebia as its new Senior Vice President, Chief Financial Officer and Treasurer, beginning on July 17, 2023.
  • Snow will join Akebia from Pear Therapeutics, Inc., where she has served as Chief Accounting Officer since 2021.
  • Snow will succeed David A. Spellman, who served as Akebia's Senior Vice President, Chief Financial Officer and Treasurer since 2020.
  • Snow served as the Chief Accounting Officer of AlerisLife Inc., a senior living and lifestyle services company, from 2019 to 2021.

Greater Philadelphia Region Seeks ARPA-H Home

Retrieved on: 
Wednesday, June 29, 2022
Drexel University, Wistar Institute, Bangladesh Technical Education Board, FDA, Chamber, Patient, Coriell Institute for Medical Research, RNA transfection, GSK, Children's Hospital of Philadelphia, HHS, Jefferson Health, Research, Senior, Johnson & Johnson, COVID-19, Commerce, International airport, Atmosphere, ARPA, NIH, PHL, Temple University, Institute for Economic Competitiveness, Letter, DARPA, Hospital, Bristol Myers Squibb, Gene editing, University, AstraZeneca, Congress, Philadelphia International Airport, Vaccine, Intention, Pharmaceutical industry, Merck, Delaware Valley, Pfizer

PHILADELPHIA, June 29, 2022 /PRNewswire/ -- The Chamber of Commerce for Greater Philadelphia today announced the region's intention to seek to be the new home for a recently announced $1 billion federal agency, the Advanced Research Projects Agency for Health (ARPA-H), which is expected to be located outside of Washington D.C.  In a letter sent to the U.S. Health & Human Services Department Secretary Xavier Becerra and signed by business, civic, and elected officials, signers tout the region's expertise in cell & gene therapy and gene editing, its rank as one of the top eight life sciences markets in the U.S., and its deep scientific and medical ecosystem as reasons why this area stands out as the ideal location. The new agency, established by Congress earlier this year, will speed up biomedical and health cures and treatment by funding new and innovative research.

Key Points: 
  • "We feel that Greater Philadelphia's position as a global hub of research, talent, capital, and companies, combined with its second-to-none accessibility, give this region the power to forever transform how care is delivered to patients and essentially cure the incurable," the letter states.
  • "Today the Chamber is launching a multi-state, eleven-county regional effort to attract the new Advanced Research Projects Agency for Health to the Greater Philadelphia region," said Claire Marrazzo Greenwood, Executive Director and Senior Vice President of Economic Competitiveness for the Chamber.
  • The Philadelphia region has a long and deep track record of innovation.
  • To date, six FDA-approved cell & gene therapies have their origins in the region.

Caron Treatment Centers Opens First-Of-Its-Kind Medical Research Center

Retrieved on: 
Tuesday, June 7, 2022
Health, Other Health, Other Science, General Health, Research, Science, Woman, BDS, FAAFP, Education, Executive, Insurance, DO, Founding, Man, Mental health, FAPA, Desert Hope Addiction Treatment Center, Center for Research and Development in Health Sciences, Marker beacon, CEO, Life, Center, Solution, Trustee, Brain, FDA, Student, Cardiovascular disease, Addiction medicine, Doctor of Philosophy, Risk, Diabetes, Caron, Coriell Institute for Medical Research, MPH, Cancer, Pharmaceutical industry, Research, MD

Caron Treatment Centers , a leading, internationally recognized nonprofit dedicated to addiction and behavioral healthcare treatment, research, prevention, and addiction medicine education, will officially open The Fran and Doug Tieman Center For Research on its Pennsylvania campus on June 7th.

Key Points: 
  • Caron Treatment Centers , a leading, internationally recognized nonprofit dedicated to addiction and behavioral healthcare treatment, research, prevention, and addiction medicine education, will officially open The Fran and Doug Tieman Center For Research on its Pennsylvania campus on June 7th.
  • The Fran and Doug Tieman Center for Research , named for Carons former President and CEO, is the first-of-its-kind to be located at a nonprofit addiction treatment facility with a focus on medical research.
  • Dr. Joseph Garbely , DO, DFASAM, FAPA, is the Chief Medical Officer and the Executive Vice President for Medical Strategy, Education and Research at Caron Treatment Centers.
  • Caron Treatment Centers is an internationally recognized nonprofit dedicated to addiction and behavioral healthcare treatment, research, prevention, and addiction medicine education.

BioLife Solutions Executes Co-Marketing Agreement with Coriell Institute for Medical Research to Offer Biostorage, Biospecimen Processing and Custom Laboratory Services

Retrieved on: 
Monday, May 9, 2022
COVID-19, U.S. Securities and Exchange Commission, Co-marketing, Private Securities Litigation Reform Act, Solution, Biomedical Research, Coriell Institute for Medical Research, Twitter, EBITDA, Immortalised cell line, NASDAQ, BLFS, Company, Contract, Drug discovery, Opioid use disorder, Baxter International, Doctor of Philosophy, Security (finance), Risk, Annual report, National, Institute, DNA, Genomics, Potency (pharmacology), Sumathi Best Television Current Reporting Award, CGT, Health, Research, Collection, Acquisition, Medical research, Pharmaceutical industry, Fine chemical

Under the terms of the agreement, BioLife, under its SciSafe brand, will promote Coriell's biospecimen processing services and Coriell will promote BioLife's biologic storage services to the scientific research and biopharma markets.

Key Points: 
  • Under the terms of the agreement, BioLife, under its SciSafe brand, will promote Coriell's biospecimen processing services and Coriell will promote BioLife's biologic storage services to the scientific research and biopharma markets.
  • Founded in 1953, the Coriell Institute for Medical Research is a nonprofit research institute dedicated to improving human health through biomedical research.
  • Coriell scientists lead research in personalized medicine, cancer biology, epigenetics, and the genomics of opioid use disorder.
  • BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets.

Malaysian Genomics Resource Centre Berhad Awarded Covid-19 Surveillance Contract

Retrieved on: 
Monday, April 4, 2022
Asset integrity management systems, CGMP, Ministry of Health (Malaysia), Genomics, Group, CAR, Cell engineering, Certification, Government, Dato, Medical research, IMR, MOH, Biosafety, Knowledge, Coriell Institute for Medical Research, Institute, COVID-19, Ministry, ISO, ISO 9001:2015, Vaccine

PETALING JAYA, Malaysia, Apr 4, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group"), a leading genomics and biopharmaceutical specialist, was recently awarded a COVID-19 surveillance contract by the Institute for Medical Research ("IMR"), the biomedical research arm of the Ministry of Health ("MOH").

Key Points: 
  • PETALING JAYA, Malaysia, Apr 4, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group"), a leading genomics and biopharmaceutical specialist, was recently awarded a COVID-19 surveillance contract by the Institute for Medical Research ("IMR"), the biomedical research arm of the Ministry of Health ("MOH").
  • Malaysian Genomics is one of the private laboratories that IMR has engaged to outsource genome surveillance of SARS-CoV2.
  • Dato' Alvin Nesakumar, Executive Director of Malaysian Genomics, said, "We are pleased to support IMR and MOH in this important effort to monitor the evolution of the COVID-19 virus, its variants and sub-variants.
  • Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/
    Copyright 2022 ACN Newswire .

BioNJ Announces Company Presenters for BioPartnering Conference

Retrieved on: 
Tuesday, March 8, 2022
Newton, Doctor of Education, Investment banking, Doctor of Pharmacy, Partnering, University, J. P. Morgan, Rowan University, MPH, Babylon Health, Princeton University, MS, MHSC, Vaccination, Conference, Education, Research, Rutgers Business School – Newark and New Brunswick, Wistar Institute, Hackensack Meridian Health, Medical Affairs Bureau, District, Multimedia, Hematology-Oncology and Stem Cell Transplantation Research Center, Coriell Institute for Medical Research, MBA, University of Pennsylvania, Sharon Wyatt, JD, Johnson & Johnson, Medical research, New Jersey Institute of Technology, Ecosystem, Process, Innovation, Liberty House Group, Dangers, Doctor of Philosophy, Janssen Pharmaceuticals, Program, Policy, CEO, Associate, Commercial bank, Pharmaceutical industry, Online shopping, Management, New York University, Insming, Hematology, Health care, Pfizer

A key component of the program remains the company and pitch presentations -- featuring early stage start-ups to later stage companies and everything in between. To ensure a platform for dynamic conversation, the company and pitch presentations will be delivered in an interactive virtual room, where investors can ask live questions and speak directly to company and pitch presenters. The application process to present is now underway with applications due no later than next Friday, March 18. Click here for details.

Key Points: 
  • TRENTON, N.J., March 8, 2022 /PRNewswire/ -- BioNJ's Twelfth Annual BioPartnering Conference , developed in concert with J.P. Morgan and Johnson & Johnson Innovation, will take place May 9-13, 2022.
  • "BioNJ's BioPartnering Conference is designed to create opportunities and foster productive partnerships as well as to grow the ecosystem and bolster medical innovation.
  • There is a place for companies at every stage of development," said BioNJ President and CEO Debbie Hart.
  • To ensure a platform for dynamic conversation, the company and pitch presentations will be delivered in an interactive virtual room, where investors can ask live questions and speak directly to company and pitch presenters.

Precision Medicine Leader Scott Megill Named One of The Top 25 Biotech CEOs of 2022

Retrieved on: 
Wednesday, February 16, 2022
Health, Adoption, CLS, Perseverance, Kenneth Megill, Coriell Institute for Medical Research, Death, Precision medicine, Medical research, Biotechnology, Research, DNA, Genetics, Economics, Medicine, Organization, Pharmaceutical industry

Megill is an influential force using PGx to tackle the issues of adverse drug events and trial-and-error prescribing.

Key Points: 
  • Megill is an influential force using PGx to tackle the issues of adverse drug events and trial-and-error prescribing.
  • "Over the past year, these leading biotechnology executives and their organizations have demonstrated ingenuity, skill, and perseverance in solving tremendous challenges.
  • From hundreds of nominees, these executives stood out for their unflagging commitment to improving lives through the advancement of medicine," noted The Healthcare Technology Report.
  • Coriell Life Sciences (CLS), a leader in genetic science, uses innovation in precision medicine to reduce healthcare costs and empower a healthier world.